Posts by Julia Ebner

Setting the Trend with Innovative Patient Engagement Strategies By: Cheryl Lubbert, CEO, published in Medhealth Review In the healthcare landscape, patient engagement has become a critical foundational element for achieving positive health outcomes, and a range of healthcare and pharmaceutical companies turn to this important approach to incorporate the patient voice throughout their programs and…

Part 3 of 3: Engaging patients before, during and after the clinical process This blog is part 3 of a series on the impact and benefits of patient involvement with the clinical trial process –  patient willingness to participate in trials, what they can contribute beyond their role as study participant and how to most…

By: Clinical Partnerships Team Part 2 of 3: How patients can improve clinical trial design This blog is part 2 of a series on the impact and benefits of patient involvement with the clinical trial process –  patient willingness to participate in trials, what they can contribute beyond their role as a study participant and…

By: Clinical Partnerships Team Once a promising new drug candidate reaches the clinic, many R&D challenges have already been overcome. But the goal of the clinical trial process to produce quality data brings a new set of challenges. The process of enrolling patients—finding not only the number of patients needed to participate, but the right…

Take a listen to this thought-provoking podcast as our CEO, Cheryl Lubbert shares her insights with pharmaphorum on best practices for engaging patients from pre-clinical through commercialization stages and beyond. Listen here https://lnkd.in/g7xyVECd In the podcast, Reverba CEO Cheryl Lubbert joins host Jonah Comstock to walk through the steps of the product life cycle and…

By: Clinical Partnerships Team It’s no secret that patient recruitment is critical for a successful clinical trial. From first patient/first dose to data lock, everything rests on enrolling (and retaining) enough participants. Otherwise, costs go up, and so does demand on resources. Treatments take longer to get to market or—worse yet—the trial gets cancelled. But…

By: Reverba Clinical Partnerships Team From first patient/first dose to data lock, everything depends on recruiting and retaining clinical trial participants. That can be quite challenging. A 2022 editorial in Clinical Trials Arena noted that the biggest reason for trial termination is low accrual rates which have accounted for 25.4% of all terminated trials. The good…

Today is Clinical Trials Day –a day where clinical trial awareness is raised and we honor clinical research professionals across the globe. In tribute, we are pleased to showcase a recent article in MedCityNews where a Health Stories Project® research study was cited, revealing that 97% of patients believe that their voice is key for…